Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study
Author
Abstract
Suggested Citation
DOI: 10.1016/j.healthpol.2023.104901
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
- Steg, Jan-Henrik & Thijssen, Jacco J.J., 2023. "Strategic investment with positive externalities," Games and Economic Behavior, Elsevier, vol. 138(C), pages 1-21.
- Lexchin, Joel, 2022. "Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study," Health Policy, Elsevier, vol. 126(10), pages 1018-1022.
- Jake An & Donnel Briley & Shai Danziger & Shai Levi, 2023. "The Impact of Social Investing on Charitable Donations," Management Science, INFORMS, vol. 69(2), pages 1264-1274, February.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Zhang, Wei & Guh, Daphne P. & Grootendorst, Paul & Hollis, Aidan & Anis, Aslam H., 2024. "The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis," Health Policy, Elsevier, vol. 144(C).
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Zhang, Wei & Guh, Daphne P. & Grootendorst, Paul & Hollis, Aidan & Anis, Aslam H., 2024. "The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis," Health Policy, Elsevier, vol. 144(C).
- Diemo Dietrich & Uwe Vollmer, 2024. "Investment externalities, bank liquidity creation, and bank failures," Journal of Economics, Springer, vol. 141(2), pages 137-162, March.
More about this item
Keywords
Canada; Drug prices; Therapeutic value; Food and Drug Administration;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:136:y:2023:i:c:s0168851023001860. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.